Cerebrospinal-fluid Alzheimer’s disease biomarkers and blood-brain barrier integrity in a natural population of cognitive intact Parkinson’s disease patients

CNS and Neurological Disorders - Drug Targets

Volumn 16, Issue 3, 2017, Pages 339-345

  Liguori, Claudio ^a   Olivola, Enrica ^a,d   Pierantozzi, Mariangela ^a   Cerroni, Rocco ^a   Galati, Salvatore ^b   Saviozzi, Valentina ^a   Mercuri, Nicola Biagio ^a,c   Stefani, Alessandro ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Motor impairment; Parkinson s disease; Tau proteins

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; SERUM ALBUMIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CELL MEMBRANE PERMEABILITY; CEREBROSPINAL FLUID; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE; COMPLICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BLOOD-BRAIN BARRIER; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS;

EID: 85038260326     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527316666161205123123     Document Type: Article

References (25)

1. Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015; 84: 57-63.
2. Alves G, Lange J, Blennow K, et al. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology 2014; 82: 1784-90.
3. Compta Y, Pereira JB, Rios J, et al. Combined dementia-risk biomarkers in Parkinson’s disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013; 19: 717-24.
4. Zhang J, Mattison HA, Liu C, et al. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 2013; 126: 671-82.
5. Terrelonge MJ, Marder KS, Weintraub D, Alcalay RN. CSF β-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed parkinson disease. J Mol Neurosci 2016; 58(1): 88-92.
6. Backstrom DC, Eriksson Domellof M, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident parkinson disease. JAMA Neurol 2015; 72(10): 1175-82.
7. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75: 1055-61.
8. Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A. CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. J Neural Transm 2012; 119: 861-75.
9. Liu C, Cholerton B, Shi M, et al. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord 2015; 21(3): 271-6.
10. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS. Association of cerebrospinal fluid beta-amyloid 1-42, t-tau, p-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013; 70: 1277-87.
11. Sengupta U, Guerrero-Munoz MJ, Castillo-Carranza DL, et al. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry 2015; 78: 672-83.
12. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003; 300: 636-40.
13. Pisani V, Stefani A, Pierantozzi M, et al. Increased bloodcerebrospinal fluid transfer of albumin in advanced Parkinson’s disease. J Neuroinflammation 2012; 9:188.
14. Carvey PM, Zhao CH, Hendey B, et al. 6-Hydroxydopamineinduced alterations in blood-brain barrier permeability. Eur J Neurosci 2005; 22: 1158-68.
15. Westin JE, Lindgren HS, Gardi J, et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 2006; 26: 9448-61.
16. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005; 57: 176-9.
17. Shi M, Kovac A, Korff A, et al. CNS tau efflux via exosomes is likely increased in Parkinson’s disease but not in Alzheimer’s disease. Alzheimers Dement 2016 May 24 [Epub ahead of print]
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
19. Fahn S, Elton R. UPDRS Program Members. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, Eds. Recent Developments in Parkinson’s disease. Florham Park, NJ: Macmillan Healthcare Information 1987; pp. 153-63.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
21. Olivola E, Pierantozzi M, Imbriani P, et al. Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart. PLoS One 2014; 9: e101763.
22. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-22.
23. Liguori C, Stefani A, Sancesario G, Sancesario GM, Marciani MG, Pierantozzi M. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2015; 86: 655-9.
24. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310: 173-86.
25. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-44.